Skip to main content



Multidisciplinary Real-World Experience With Bilastine, a Second Generation Antihistamine

By Eprint, Noticias

Lynde CW, Sussman G, Dion PL, Guenther L, Hébert J, Rao J, Leek TV, Waserman S. J Drugs Dermatol. 2020 Feb 1;19(2):145-154. doi: 10.36849/JDD.2020.4835.

Allergic conditions, such as seasonal allergic rhinitis, perennial allergic rhinitis (PAR), and urticaria (both acute and chronic) are frequently treated with H1-antihistamines. However, first-generation H1-antihistamines cause impairment and potentially interfere with restful sleep, cause hangovers or “morning after” effects, impair learning and memory, and reduce work efficiency. Second generation antihistamines, such as bilastine have shown to decrease allergy symptoms effectively without causing night-time sleep disturbances and related adverse events.

Bilastine is a prescription medicine. It is not derived from nor is it a metabolite of another antihistamine, has a rapid one-hour onset of action and provides sustained efficacy. Bilastine does not penetrate the brain, is scarcely metabolized and does not interact with cytochrome P450. For the treatment of allergic conditions in adults and children over 12 years of age, a daily oral dose of bilastine 20 mg is recommended. ç

This real world case project was developed to help optimize patient care and supported with evidence from the literature. It included patients between 9 and 76 years old with seasonal allergic rhinitis, perennial allergic rhinitis and chronic and acute urticaria as well as urticarial vasculitis and pruritus associated with inflammatory skin conditions. The presented cases using bilastine showed positive outcomes for the patients, relieving symptoms with safety and good tolerance.

Sólo profesionales sanitarios registrados pueden acceder a esta publicación


Bilastine: a lifetime companion for the treatment of allergies

By Eprint

Martin K Church, Marysia Tiongco-Recto, Erminia Ridolo & Zoltán Novàk.

(2019) Current Medical Research and Opinion, DOI: 10.1080/03007995.2019.1681134

Bilastine is a potent and highly selective H1-antihistamine for the treatment of urticaria and allergic rhinoconjunctivitis.

This is a review article that gathers information available up to 25 February 2019 on the use of the H1-antihistamine bilastine in the treatment of allergic disorders in different age groups, from children to adults.

Teenagers and adults bilastine dose is usually 20 mg daily and children up to 12 years old is 10 mg of bilastine once daily. Bilastine has demonstrated efficacy at improving allergic rhinitis symptoms, such as nasal and ocular symptoms and at improving wheals and itching in urticaria. It has a rapid onset of action and a long duration of action.

Bilastine does not interact with the CYP450 system, making it a H1-antihistamine free from drug-drug interactions. Patients with renal or hepatic impairment or elderly ones don’t need dosage adjustment. Bilastine is well tolerated, even at above standard doses and doesn’t exhibit anticholinergic or cardiotoxic effects. It has minimal sedative properties due to its inexistence central nervous system penetration. Patients on bilastine show an overall improvement of health-related quality of life.

In conclusion, bilastine is a suitable option of H1-antihistamins for the treatment of allergic rhinoconjunctivitis or urticaria in all patients.

This document is only available for registered healthcare professionals.

Eficacia y seguridad de bilastina para reducir el prurito en pacientes con urticaria crónica espontánea y otras enfermedades de la piel: un estudio exploratorio

Efficacy and safety of bilastine in reducing pruritus in patients with chronic spontaneous urticaria and other skin diseases: an exploratory study

By Eprint

Esther Serra, Cristina Campo, Zoltan Novak, Bernadetta Majorek-Olechowska, Grazyna Pulka, Aintzane García-Bea and Luis Labeaga

Se realizó un estudio exploratorio de fase IV, multicéntrico, abierto para evaluar la eficacia y la seguridad de bilastina en la reducción del prurito en pacientes con urticaria crónica espontánea y otras enfermedades de la piel en 10 centros europeos.
El estudio concluyó que bilastina ha demostrado ser eficaz para el alivio del prurito asociado con la urticaria y otras enfermedades de la piel en adultos, con un perfil de seguridad muy bueno. Además, la bilastina hasta la dosis de 40 mg (dosis doble), para los pacientes que no lograron una mejoría significativa después de 2 semanas de tratamiento, fue eficaz sin ningún problema de seguridad.

Sólo profesionales sanitarios registrados pueden acceder a esta publicación.

Urticaria Espontánea Crónica (UCE)

Diagnosis, pathogenosis, and treatment of chronic spontaneous urticaria (e-Print)

By Eprint
Allen P, Kaplan M.D.

Diagnóstico, patogénesis y tratamiento de la Urticaria Espontánea Crónica (UEC)

Dosis altas de antihistamínicos, omalizumab y ciclosporina (en este orden) son efectivas y recomendables para la terapia de la Urticaria Espontánea Crónica (UEC) (CSU en sus siglas en Inglés), una enfermedad inflamatoria de la piel asociada con la autoinmunidad en el 45% de los pacientes.

e-Print. Descarga gratuita hasta fin de unidades contratadas.
Sólo profesionales sanitarios registrados pueden ver este documento

Close Menu

La información que está a punto de visualizar está dirigida únicamente a los profesionales sanitarios aptos para prescribir o dispensar medicamentos. La correcta utilización de su contenido requiere de formación como profesional sanitario.

Debe hacer clic en Aceptar para confirmar que es usted profesional de la salud y continuar con la navegación.